What’s New in Bioanalysis?

Stem Cells

Stem Cell Therapies: Close to Transforming Promise into Real Patient Outcomes

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Rare Cancer CGT

Developing Cell and Gene Therapies for Rare Oncology Applications

David Alvaro, Ph.D.

Pharma's Almanac

Data Integrity

Data Integrity: Drivers, Challenges, and Key Program Elements

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Adaptive Trials

Designing for Change: Adaptive Clinical Trials and the Evolving Path to Regulatory Acceptance

Pharma's Almanac

Personalized

Regulatory Innovation for a More Personalized Era of Medicine

Pharma's Almanac

CRO Partnerships

Building Resilient Development Models: How Mid-Size Pharma Can Scale Without Losing Control

Brian Healey

IQVIA

Expedited Pathways

Accelerated Pathways: Are They Delivering on Their Promise?

David Alvaro, Ph.D.

Pharma's Almanac

Clinical Evidence

Rethinking Clinical Evidence Requirements in Rare Diseases

David Alvaro, Ph.D.

Pharma's Almanac

Supply Chain

Outsourcing, Fragmentation, and the New Supply Chain Resilience Challenge

Pharma's Almanac

Outsourcing

The Hidden Operational Costs of Multi-Vendor Outsourcing Models

Pharma's Almanac

AI in Manufacturing

Validating and Governing AI in GMP Manufacturing

Pharma's Almanac

AI Data Integrity

Data Integrity in the Age of AI-Assisted Manufacturing

Pharma's Almanac